119th Congress (2025-2026)

HR 685

SAVE Moms and Babies Act of 2025

Introduced

Jurisdiction

US Congress

Session

119th Congress (2025-2026)

Official source

Chamber

House

Session

119th Congress (2025-2026)

Jurisdiction

US Congress

Bill overview

The SAVE Moms and Babies Act of 2025 prohibits the FDA from approving new drugs intended to terminate pregnancies and imposes stricter regulations on already-approved drugs used for abortion. It requires in-person prescription dispensing, limits the gestational age at which such drugs can be used, and mandates additional training and certification for healthcare practitioners prescribing these drugs. The bill also rescinds existing investigational use exemptions for abortion drugs and requires reporting of adverse events.

Key provisions

Prohibits approval of new abortion drugs.
Requires in-person prescription dispensing of approved abortion drugs.
Limits the gestational age at which abortion drugs can be used to 70 days.
Requires healthcare practitioners prescribing abortion drugs to be certified and prohibited from acting as pharmacists.
Mandates reporting of adverse events associated with abortion drug use.
Rescinds investigational use exemptions for abortion drugs.
Requires reporting of administration of abortion drugs as required by State law.
Defines ‘abortion drug’ to exclude drugs used for live birth, removal of dead unborn children, or treatment of ectopic pregnancies.

Who is affected

Pharmaceutical companies
Healthcare practitioners (prescribers)
Pregnant women
The Food and Drug Administration (FDA)
Patients seeking abortion care

Notable changes

Positions across the country

No public positions recorded for this legislation.

Arguments in favor

Reasons to support this legislation.

No arguments in favor have been submitted.

Submit yours

Arguments opposed

Reasons to oppose this legislation.

No arguments opposed have been submitted.

Submit yours

Legislative history

2025-01-23House

Referred to the House Committee on Energy and Commerce.

2025-01-23

Introduced in House

2025-01-23

Introduced in House

Read the latest version inline or switch to a previous version.

Jan 23, 2025XMLView source

119th CONGRESS — 1st Session

H. R. 685

IN THE HOUSE OF REPRESENTATIVES

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to prohibit the approval of new abortion drugs, to prohibit investigational use exemptions for abortion drugs, and to impose additional regulatory requirements with respect to previously approved abortion drugs, and for other purposes.

1.Short title

This Act may be cited as the

Support And Value Expectant Moms and Babies Act of 2025

or the

SAVE Moms and Babies Act of 2025

2.Abortion drugs prohibited

(a)In generalSection 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) (as amended by Public Law 117–328) is amended by adding at the end the following:

(aa)Abortion drugs

(1)ProhibitionsThe Secretary shall not approve—

(A)

any application submitted under subsection (b) or (j) for marketing an abortion drug; or

(B)

grant an investigational use exemption under subsection (i) for—

(i)

an abortion drug; or

(ii)any investigation in which the unborn child of a woman known to be pregnant is knowingly destroyed.

(2)Previously approved abortion drugsIf an approval described in paragraph (1) is in effect for an abortion drug as of the date of enactment of the

Support And Value Expectant Moms and Babies Act of 2025

, the Secretary shall—

(A)

not approve any labeling change—

(i)

to approve the use of such abortion drug after 70 days gestation; or

(ii)

to approve the dispensing of such abortion drug by any means other than in-person administration by the prescribing health care practitioner;

(B)

treat such abortion drug as subject to section 503(b)(1); and

(C)

require such abortion drug to be subject to a risk evaluation and mitigation strategy under section 505–1 that at a minimum—

(i)requires health care practitioners who prescribe such abortion drug—

(I)

to be certified in accordance with the strategy; and

(II)

to not be acting in their capacity as a pharmacist;

(ii)as part of the certification process referred to in clause (i), requires such practitioners—

(I)

to have the ability to assess the duration of pregnancy accurately;

(II)

to have the ability to diagnose ectopic pregnancies;

(III)

to have the ability to provide surgical intervention in cases of incomplete abortion or severe bleeding;

(IV)

to have the ability to ensure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary; and

(V)

to report any deaths or other adverse events associated with the use of such abortion drug to the Food and Drug Administration and to the manufacturer of such abortion drug, identifying the patient by a non-identifiable reference and the serial number from each package of such abortion drug;

(iii)

limits the dispensing of such abortion drug to patients—

(I)in a clinic, medical office, or hospital by means of in-person administration by the prescribing health care practitioner; and

(II)

not in pharmacies or any setting other than the health care settings described in subclause (I);

(iv)

requires the prescribing health care practitioner to give to the patient documentation on any risk of serious complications associated with use of such abortion drug and receive acknowledgment of such receipt from the patient;

(v)

requires all known adverse events associated with such abortion drug to be reported, excluding any individually identifiable patient information, to the Food and Drug Administration by the—

(I)

manufacturers of such abortion drug; and

(II)

prescribers of such abortion drug; and

(vi)requires reporting of administration of the abortion drug as required by State law, or in the absence of a State law regarding such reporting, in the same manner as a surgical abortion.

(3)Reporting on adverse events by other health care practitionersThe Secretary shall require all other health care practitioners to report to the Food and Drug Administration any adverse events experienced by their patients that are connected to use of an abortion drug, excluding any individually identifiable patient information.

(4)Rule of construction

Nothing in this section shall be construed to restrict the authority of the Federal Government, or of a State, to establish, implement, and enforce requirements and restrictions with respect to abortion drugs under provisions of law other than this section that are in addition to the requirements and restrictions under this section.

(5)DefinitionsIn this section:

(A)The term abortion drug means any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than—

(i)

to produce a live birth;

(ii)

to remove a dead unborn child; or

(iii)

to treat an ectopic pregnancy.

(B)

The term adverse event includes each of the following:

(i)

A fatality.

(ii)

An ectopic pregnancy.

(iii)

A hospitalization.

(iv)

A blood loss requiring a transfusion.

(v)

An infection, including endometritis, pelvic inflammatory disease, and pelvic infections with sepsis.

(vi)

A severe infection.

(C)The term gestation means the period of days beginning on the first day of the last menstrual period.

(D)The term health care practitioner means any individual who is licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which the individual practices, to prescribe drugs subject to section 503(b)(1).

(E)The term unborn child means an individual organism of the species homo sapiens, beginning at fertilization, until the point of being born alive as defined in section 8(b) of title 1, United States Code.

(b)Ongoing investigational useIn the case of any investigational use of a drug pursuant to an investigational use exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) that was granted before the date of enactment of this Act, such exemption is deemed to be rescinded as of the day that is 3 years after the date of enactment of this Act if the Secretary would be prohibited by section 505(aa)(1)(B) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), from granting such exemption as of such day.

HR 685